hVIVO PLC Exercise of Warrants (0209L)

TIDMHVO

RNS Number : 0209L

hVIVO PLC

01 September 2023

hVIVO plc

("hVIVO" or the "Company")

Exercise of Warrants

hVIVO plc (AIM & Euronext: HVO) has received notice of exercise of warrants by a former nomad and corporate finance advisor (awarded as part of the IPO of the Company in June 2019), over 1,607,142 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") at a price of 5.6 pence per share. The gross proceeds of this exercise received by the Company amount to GBP90,000.

The total remaining outstanding warrants over Ordinary Shares are as follows:

 
 Number of Ordinary   Exercise Price   Date awarded    Expiry Date        Beneficiary 
       Shares            per share 
      232,696           0.1 pence      11 December   10 December 2023   Venn loan note 
                                           2018                         investor (Cathal 
                                                                             Friel) 
                     ---------------  -------------  ----------------  ----------------- 
      424,589           2.2 pence      11 December   10 December 2023   Venn loan note 
                                           2018                             investor 
                                                                         (Cathal Friel) 
                     ---------------  -------------  ----------------  -----------------

The Company has made application for 1,607,142 new Ordinary Shares, to be issued and allotted as a result of the warrant exercise set out above, to be admitted to trading on AIM and Euronext Growth. Admission is expected to occur at 8.00 a.m. on 6 September 2023.

Total Voting Rights

Following the admission of the 1,607,142 new Ordinary Shares, the Company's total issued ordinary share capital will consist of 680,371,877 Ordinary Shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For further information please contact:

 
 hVIVO plc                                                           +44 (0) 20 7756 1300 
 Yamin 'Mo' Khan, Chief Executive 
  Officer 
  Stephen Pinkerton, Chief Financial 
  Officer 
 
 Liberum Capital (Nominated Adviser and 
  Joint Broker)                                                      +44 (0) 20 3100 2000 
 Ben Cryer, Edward Mansfield, Phil Walker, 
  Will King 
 
 finnCap plc (Joint Broker)                                          +44 (0) 20 7220 0500 
 Geoff Nash, Charlie Beeson, Nigel Birks, 
  Harriet Ward (ECM) 
 
 Davy (Euronext Growth Adviser and Joint 
  Broker)                                                             +353 (0) 1 679 6363 
 Anthony Farrell, Niall Gilchrist 
 
 Walbrook PR (Financial PR & IR)             +44 (0) 20 7933 8780 or hvivo@walbrookpr.com 
  Stephanie Cuthbert / Phillip                    +44 (0) 7796 794 663 / +44 (0) 7867 984 
  Marriage /                                                                        082 / 
  Louis Ashe-Jepson                                                  +44 (0) 7747 515 393

Notes to Editors

About hVIVO

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Company has world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREAKPFDDKDEFA

(END) Dow Jones Newswires

September 01, 2023 02:00 ET (06:00 GMT)

hVIVO (AQSE:HVO.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024